Methotrexate-vindesine Association in the Treatment of Head and Neck Cancer Influence of Vindesine on Methotrexate's Pharmacokinetic Behavior

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1984 Jan 1

PMID 6697425

Citations 2

Authors

N Lena

A M Imbert

T Pignon

R Favre

G Meyer

J P Cano

Y Carcassonne

Affiliations

Soon will be listed here.

Abstract

Determination of methotrexate (MTX) kinetics after an IV bolus (50 mg/m2) allows prediction of the steady-state plasma level of this drug during a constant infusion. This prediction allows high-dose MTX (HD-MTX) therapy without major toxicity. Patients with head and neck carcinoma received HD-MTX and vindesine (VDS) infusions concomitantly. The therapeutic survey of these patients showed that the predicted plasma level of MTX was not achieved in the presence of VDS. Moreover, the computed dose of MTX had to be increased by a larger amount if the MTX plasma clearance after the identification IV push was low (less than 9 l/h). In the presence of VDS, the creatinine clearance is lower than when MTX is infused alone, and MTX renal elimination is identical (MTX or MTX + VDS infusions). Thus it seems that the decrease of the MTX plasma level during MTX-VDS infusion could be due to an increase of cellular incorporation.

Citing Articles

Methotrexate-vindesine association in leukemia: pharmacokinetic study.

Tubiana N, Lena N, Barbet J, Imbert A, Lejeune C, Maraninchi D Med Oncol Tumor Pharmacother. 1985; 2(2):99-102.

PMID: 3864001 DOI: 10.1007/BF02934855.

Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine.

Bore P, Lena N, Imbert A, Favre R, Cano J, Meyer G Cancer Chemother Pharmacol. 1986; 17(2):171-6.

PMID: 3719898 DOI: 10.1007/BF00306749.

References

Sirotnak F, Donsback R . Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Cancer Res. 1975; 35(7):1737-44. View

Bertino J, Fischer G . TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS. Methods Med Res. 1964; 10:297-307. View

Zager R, Frisby S, OLIVERIO V . The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res. 1973; 33(7):1670-6. View

Levitt M, Mosher M, DeConti R, Farber L, Skeel R, Marsh J . Improved therapeutic index of methotrexate with "leucovorin rescue". Cancer Res. 1973; 33(7):1729-34. View

Bischoff K, Dedrick R, ZAHARKO D, Longstreth J . Methotrexate pharmacokinetics. J Pharm Sci. 1971; 60(8):1128-33. DOI: 10.1002/jps.2600600803. View

Goldman I, Gupta V, White J, Loftfield S . Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols. Cancer Res. 1976; 36(1):276-9. View

DeConti R, Schoenfeld D . A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer. 1981; 48(5):1061-72. DOI: 10.1002/1097-0142(19810901)48:5<1061::aid-cncr2820480502>3.0.co;2-x. View

Fyfe M, Goldman I . Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells. J Biol Chem. 1973; 248(14):5067-73. View

Favre R, Monjanel S, Alfonsi M, Pradoura J, Clement S, Imbert A . High-dose methotrexate: a clinical and pharmacokinetic evaluation. Treatment of advanced squamous cell carcinoma of the head and neck using a prospective mathematical model and pharmacokinetic surveillance. Cancer Chemother Pharmacol. 1982; 9(3):156-60. DOI: 10.1007/BF00257744. View

10.

Chello P, Sirotnak F, Dorick D . Different effects of vincristine on methotrexate uptake by L1210 cells and mouse intestinal epithelia in vitro and in vivo. Cancer Res. 1979; 39(6 Pt 1):2106-12. View

11.

CAPIZZI R, DeConti R, Marsh J, Bertino J . Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". Cancer Res. 1970; 30(6):1782-8. View

12.

Goldman I . Membrane transport considerations in high-dose methotrexate regimens with leucovorin rescue. Cancer Treat Rep. 1981; 65 Suppl 1:13-7. View

13.

White J . Recent concepts on the mechanism of action of methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:3-12. View

14.

Cheng E, Young C, Wittes R . Phase II trial of vindesine in advanced head and neck cancer. Cancer Treat Rep. 1980; 64(10-11):1141-2. View

15.

Fyfe M, Loftfield S, Goldman I . A reduction in energy-dependent amino acid transport by microtubular inhibitors in Ehrlich ascites tumor cells. J Cell Physiol. 1975; 86(2 Pt 1):201-11. DOI: 10.1002/jcp.1040860203. View

16.

Monjanel S, Rigault J, Cano J, Carcassonne Y, Favre R . High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol. 1979; 3(3):189-96. DOI: 10.1007/BF00262421. View

17.

Chabner B, Young R . Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973; 52(8):1804-11. PMC: 302460. DOI: 10.1172/JCI107362. View

18.

Chello P, Sirotnak F . Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia. Cancer Treat Rep. 1981; 65(11-12):1049-53. View